Gijón, 21st July 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, announced a research agreement with the University Medical Center of Utrecht (The Netherlands) and Artizan Biosciences [...]
Gijón, July 7, 2022, Microviable Therapeutics SL, a biotechnology company in preclinical stage developing novel microbiome-derived biotherapeutic products, today announced that it has entered into a research contract with Venter Pharma SL. and Inmunomet [...]
Microviable Therapeutics SL, a preclinical stage biotechnology company developing orally administered biological drugs based on microbiota-derived products, announced 1.5 million euros seed funding from the private medical group Inmunomet Intolerancia y Disbiosis SL. Microviable [...]